Roche Holding AG

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

AbbVie

Amgen

Biogen

Celgene

Gilead Sciences

Eli Lilly

Novo Nordisk

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Here's how these biotech stocks became the biggest on the market -- and how their future prospects look.

The 10 Biggest Biotech Stocks

Sometimes, you hear the bad news from a friend of a friend.

Oh, By the Way, This Clinical Trial Didn't Work

Roche received accelerated FDA approval for its drug Polivy to treat patients with relapsed/refractory diffuse large B-cell lymphoma.

Roche Notches An FDA Approval Under Its Belt, Along With Pipeline Momentum

Roche's (RHHBY) oncology portfolio gets a boost with the approval of Rozlytrek for neurotrophic tyrosine receptor kinase fusion-positive, advanced recurrent solid tumors.

Roche's Rozlytrek Gets Approval in Japan for Solid Tumors

Spark Therapeutics

uniQure

Gene therapy player Uniqure could head to the auction block, an analyst said Monday as shares of the biotech company popped. He also said Roche's plan to buy Spark Therapeutics could falter.

Why This Gene Therapy Stock Looks Like A Sure Takeover Bet: Analyst

AstraZeneca

Biohaven Pharmaceutical Hld

Johnson & Johnson

Merck

Alzheimer's treatment continues to confound biotech companies in the wake of Biogen and Eisai's decision to terminate two late-stage tests. But scientists say there's hope in new theories.

Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures

Roche (RHHBY) announces positive data on rheumatic diseases drug, Rituxan, for pemphigus vulgaris.

Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris

Roche (RHHBY) gets Priority Review status from the FDA for Rituxan in children with two rare blood vessel disorders.

Roche's Rituxan Gets Priority Review for Blood Disorder

Pfizer

The large-cap pharma industry is doing well in 2019. Here are three stocks from the space that investors may consider betting on.

Boost Your Portfolio's Health With These 3 Big Drug Stocks

Roche's (RHHBY) hematology portfolio gets a boost as FDA approves Polivy for DLBCL, and lymphoma drug, Gazyva, meets goals in a phase II study.

Roche's Polivy Gets FDA Nod, Gazyva Meets Goals in Phase II

Swiss drugmaker Roche on Tuesday named a new head of its $13-billion-per-year diagnostics business and also said board member Peter Voser is stepping down to focus on his expanded duties as interim head of Swiss engineering group ABB.

Roche names new head of $13 billion diagnostics unit

Swiss drug giant Roche Holdings AG Basel ADR (OTC: RHHBY) has announced another delay in its proposed takeover of the gene therapy biotech Spark Therapeutics Inc (NASDAQ: ONCE).

Roche Extends Deadline For Spark Acquisition As US, UK Regulators Seek Additional Information

The U.S. Food and Drug Administration said Monday it had approved the first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma.

FDA approves Genentech's Polivy as part of first chemoimmunotherapy regimen for patients with diffuse large B-cell lymphoma

Spark Therapeutics stock tumbled Monday after Swiss biopharma Roche delayed its $4.8 billion takeover of the biotech as regulators in the U.S. and Europe scrutinized the transaction.

Roche's $4.8 Billion Buyout Of Spark Delayed Amid Competitive Worries

Roche (RHHBY) gets additional information request from FTC for the pending Spark acquisition.

Roche Receives FTC Request for Further Data on Spark Buyout

Swiss drugmaker Roche's $4.3 billion takeover of U.S. gene therapy specialist Spark Therapeutics has been pushed back again, possibly beyond the first half, as regulators continue to scrutinize the deal for its effect on competition.

Roche's $4.3 billion Spark bid delayed again amid U.S., UK scrutiny

Bristol-Myers

Sanofi

Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.

Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache

Novartis

The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.

Was ASCO Quieter for Big Drug/Biotech Stocks This Year?

Roche Holding’s (NASDAQ:RHHBY) stock price has gained 7% year-to-date, higher than a little over a 1% gain for the Dow Jones U.S. Healthcare Index.

What Is Roche Holding's Fair Price Estimate Based On Expected 2019 Earnings?

Roche (RHHBY) reports positive data from late-stage studies on allergic asthma drug, Xolair, for a new indication, and additional results on Tecentriq and Avastin combo at ASCO.

Roche Presents Positive Data on Xolair & Updates From ASCO

Roche's (RHHBY) performance has been strong in the year so far, driven by solid growth of Ocrevus, Perjeta, Tecentriq and Hemlibra.

Roche (RHHBY) Up 6.3% YTD on Strong Demand for New Drugs

Celgene's (CELG) Revlimid in combination with a rituximab product gets FDA approval for the treatment of adult patients with previously treated follicular lymphoma or marginal zone lymphoma.

Celgene's Revlimid-Rituximab Combo Gets FDA Nod for Lymphoma

Roche (RHHBY) gets FDA clearance for the expansion of its leading testing menu.

Roche Gets FDA Nod for Expansion of Cobas 6800/8800 Systems

Synlogic

Synlogic (SYBX) announces clinical collaboration with Roche to develop its pre-clinical cancer candidate in combination with Roche's PD-L1 inhibitor, Tecentriq.

Synlogic (SYBX) Enters Cancer Collaboration with Roche

Roche (RHHBY) gains an FDA nod for the sNDA of its leukemia drug, Venclexta, in combination with Gazyva for the treatment of previously untreated chronic lymphocytic leukemia.

News for Roche Holding AG Stock (RHHBY)